AUS
NZ
UK
CA
USA
IND
Healthcare
Smith & Nephew FTSE Healthcare Market Presence and Operational Developments
March 02, 2026 01:12 PM GMT| By Vivek SinghHighlights,Global healthcare equipment operations within the medical technology sector.,Business activity across orthopaedics, wound care, sports medicine and ENT segments.,Corporate structure, financial framework and positioning within major UK indi...
FTSE Market Insight: Tristel Earnings Spark Sector-Wide Focus
March 02, 2026 12:49 PM GMT| By Team Kalkine MediaTristel’s earnings update highlights the growing strategic importance of healthcare hygiene in the UK market, reinforcing infection control as a long-term structural investment theme.
UK Biotechnology Landscape and FTSE 350 Exposure Through ONT
March 02, 2026 12:46 PM GMT| By Vivek SinghHighlights,Oxford Nanopore Technologies (LSE:ONT) operates in the advanced life sciences and genomics sector, focusing on molecular sensing and nanopore-based sequencing technologies.,The company maintains a visible position within the UK equity mark...
Roquefort Therapeutics Secures Cancer Drug Licence and Funding Boost
March 02, 2026 12:38 PM GMT| By Vivek SinghRoquefort Therapeutics acquires AO-252 cancer drug licence, enhancing clinical-stage oncology pipeline and securing funds for development and strategic growth.
PureTech Health in the FTSE landscape as technical momentum shifts
February 27, 2026 12:41 PM GMT| By Vivek SinghHighlights,UK biotechnology company operating in the life sciences and healthcare innovation sector,Active presence within the broader FTSE market framework and UK equity ecosystem,Business model structured around scientific research, development pla...
GSK (LSE:GSK) Shares Rise Amid Asia Regulatory Moves and 35Pharma Deal
February 27, 2026 12:01 PM GMT| By Vivek SinghGSK updates pipeline with Asia regulatory approvals and 35Pharma acquisition, strengthening growth prospects ahead of first-quarter results.
AstraZeneca’s Oncology Drive Gains Momentum on LSE
February 27, 2026 10:27 AM GMT| By Vivek SinghAstraZeneca advances oncology and respiratory therapies with new approvals and filings, strengthening its footprint across the LSE & FTSE stock market and reinforcing its long-term healthcare growth strategy.
GSK Share Price Swings: Is Value Emerging Now?
February 27, 2026 09:55 AM GMT| By Vivek SinghAn in-depth look at GSK’s valuation after recent volatility, exploring share price trends, growth outlook, pipeline risks, and its position within the UK equity market.
GSK Strengthens Respiratory & Kidney Pipeline With Key Deals
February 26, 2026 03:21 PM GMT| By Vivek SinghGSK expands respiratory and kidney pipeline with new acquisitions and gene silencing deals in Canada and China.
AstraZeneca Gains Fresh Oncology Edge With Key Approvals
February 26, 2026 03:16 PM GMT| By Vivek SinghAstraZeneca advances its oncology leadership as CALQUENCE and ENHERTU achieve new regulatory milestones, reinforcing its strategy across blood cancers and HER2 positive breast cancer markets.
FTSE Momentum: GSK Ignites UK Pharma Dealmaking
February 25, 2026 11:10 AM GMT| By Team Kalkine MediaA strategic pharmaceutical partnership strengthens innovation, supports UK healthcare leadership, and reinforces long‑term confidence in the evolving life sciences ecosystem.
Is FTSE 100 Reassessing GSK?
February 25, 2026 10:32 AM GMT| By Vivek SinghPharmaceutical heavyweight GSK remains central to FTSE discourse as valuation frameworks and sector themes shape its standing within the flagship UK benchmark.
AstraZeneca’s Place Within FTSE 350 Landscape
February 25, 2026 10:31 AM GMT| By Vivek SinghAstraZeneca’s role within the FTSE 100 reflects the strength of the UK pharmaceutical sector and its influence on benchmark composition and market discussions.
Is FTSE AIM 100 Index Watching HUTCHMED?
February 24, 2026 06:45 PM GMT| By Vivek SinghOncology focused HUTCHMED remains a visible constituent of the FTSE AIM benchmark, reflecting its research platform and commercial presence within the UK equity landscape.
AstraZeneca Advances Oncology Portfolio with Key Regulatory Milestones
February 24, 2026 04:55 PM GMT| By Vivek SinghExplore AstraZeneca’s latest oncology approvals and regulatory milestones, enhancing its presence in leukemia, breast cancer, and rare lymphoma markets.
Oxford BioMedica (LSE:OXB) Shares Drop Ahead of EQT Deadline
February 24, 2026 12:10 PM GMT| By Vivek SinghExplore Oxford BioMedica's trading update, revenue growth, and EQT bid overhang, with insights on FTSE 100 shares price and UK stock market trends.
FTSE Spotlight: Convatec’s Market Momentum Ignites Sector Confidence
February 24, 2026 11:00 AM GMT| By Vivek SinghConvatec’s renewed outlook reflects a broader shift in healthcare sentiment, reinforcing the sector’s role as a stable, innovative and strategically essential force within the UK market ecosystem.
Cizzle Biotech Royalty Deal Fuels US Launch Momentum
February 23, 2026 11:09 AM GMT| By Vivek SinghCizzle Biotechnology Holdings PLC (LSE:CIZ) strengthens its US expansion plans with extended royalty arrangements and progress toward commercial launch of its lung cancer biomarker test, reinforcing its diagnostics strategy and market presence.
AIM Market Focus on SkinBioTherapeutics Governance Review
February 20, 2026 08:45 AM GMT| By Vivek SinghAn AIM biotech enters a governance review phase, strengthening transparency, reshaping market confidence, and reflecting the growing importance of accountability across UK equity markets.
GSK Share Momentum Sparks Valuation Debate
February 20, 2026 04:13 AM GMT| By Vivek SinghGSK share momentum sparks valuation discussion as market sentiment focuses on pipeline strength, regulatory developments, and long-term outlook within the LSE & FTSE stock market and broader pharmaceutical sector.
